All In Biotech

NDA 204168 · Abbvie

Fetzima

Levomilnacipran Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jul 25, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

73

24 Phase 3, 1 recruiting

FAERS reports

1,929

1,027 serious, 176 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 ) ] . FETZIMA is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 ) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) . FETZIMA is not approved for use in pediatric patients ( 8.4 ).

What it is approved for

From the label in effect Apr 30, 2024.

FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults ( 1 ). Limitation of Use : FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established ( 1 ).

Mechanism: The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 120MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 40MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 80MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 20MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Levomilnacipran" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use350
  • drug ineffective266
  • pain225
  • vomiting221
  • memory impairment205
  • hypoaesthesia198
  • abdominal pain upper196
  • paraesthesia192
  • gastrooesophageal reflux disease185
  • migraine183
  • drug intolerance177
  • epilepsy168

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
2014142
2015214
2016307
2017224
2018123
2019174
2020100
2021112
2022122
2023111
202473
2025158
202668

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fetzima (Levomilnacipran HCl)

2024 spending

$27.1M

Beneficiaries

5,792

39,287 claims

Per beneficiary

$4,676

$16.46 per unit

View as table
YearSpending
2020$30,568,516
2021$29,762,191
2022$29,783,745
2023$29,339,819
2024$27,083,755

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 37 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.